Key result
Approximately 25% of patients experience a subtherapeutic antiplatelet response to clopidogrel, prompting the US FDA to highlight the impact of CYP2C19 genotype on clinical response.
Why the study?
Does CYP2C19 variant allele carrier status increase the risk of inadequate platelet inhibition and adverse cardiovascular events in CAD patients treated with clopidogrel?
Population
Coronary artery disease patients undergoing percutaneous coronary intervention
Comparison
Clopidogrel vs Wild-type CYP2C19 individuals
Design
Review
Authors
Loading...
Alerts clinicians to CYP2C19-related clopidogrel risks in CAD; leaves open whether genotyping improves outcomes without randomized data.
Does CYP2C19 variant allele carrier status increase the risk of inadequate platelet inhibition and adverse cardiovascular events in CAD patients treated with clopidogrel?
The US FDA has updated clopidogrel prescribing information to highlight the increased risk of adverse cardiovascular events in CYP2C19 variant allele carriers due to inadequate platelet inhibition.
Ellis et al. (2009) conducted a review in Coronary artery disease. Clopidogrel was evaluated. Approximately 25% of patients experience a subtherapeutic antiplatelet response to clopidogrel, prompting the US FDA to highlight the impact of CYP2C19 genotype on clinical response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: